<DOC>
	<DOCNO>NCT01158170</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy brain may effective prevent brain metastasis patient advance non-small cell lung cancer . It yet know whether radiation therapy effective observation patient advance non-small cell lung cancer . PURPOSE : This randomized phase III trial study radiation therapy brain see well work compare observation prevent brain metastasis patient advance non-small cell lung cancer</brief_summary>
	<brief_title>Prophylactic Cranial Irradiation Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer ( NSCLC ) ( RT1001 )</brief_title>
	<detailed_description>OBJECTIVES : Primary Determine effectiveness prophylactic cranial radiotherapy patient advance non-small cell lung cancer responsive gefitinib erlotinib hydrochloride . Secondary Determine progression-free survival patient treat regimen . Determine overall survival patient treat regimen . Determine safety tolerability regimen patient . Determine psycho-neurological effect regimen patient . Determine quality life patient treat regimen . OUTLINE : This multicenter study . Patients good response ( CR/PR ) EGFR-TKI ( Erlotinib Gefitinib ) randomize receive EGFR-TKI plus PCI EGFR-TKI alone , stratify accord prior chemotherapy regimen ( first line v second line ) , disease response status . Group 1 : Patients undergo prophylactic brain radiotherapy . Group 2 : Patients undergo observation . Patients complete quality life questionnaire periodically . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Patients require histologically cytologically documented 2 . NSCLC brain metastasis document magnetic resonance imaging ( MRI ) within 21 day confirm response ( RR+SD ) chemotherapy 3 . No previous history radiotherapy surgery brain 4. good response ( CR/PR ) Erlotinib Gefitinib . 5 . Agree radiotherapy 6. age &gt; 18 &lt; 75 year , ECOG performance status 1 less 7 . Good renal hepatic haematological ( absolute neutrophil count 15 x1O9/L platelet count 90 x 109/L , HB &gt; =80g /DL ) function 8 . Have provide informed consent 1 . Seizure control drug 2 . Combined disease brain tumour infarction 3 . Hypersensitivity MR enhancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>nonsmall cell lung cancer</keyword>
	<keyword>brain metastasis</keyword>
	<keyword>prophylactic cranial irradiation</keyword>
</DOC>